DAB2IP and colorectal cancer: More recently, the same group reported that in a fraction of colorectal cancers DAB2IP is mutated or silenced regardless of RAS or BRAF mutation, strongly indicating that DAB2IP loss-of-function may provide aggressive phenotypes independently of RAS hyperactivation [20].